For those interested in ALCAR for CIPN, I gathered the previous studies below just to have them in one place for reference.

Professor Bianchi is near me in Switzerland and has agreed to meet with me in the past.

I was thinking of asking him what he thinks of this latest big study contradicting his small study below.

Does anyone have any suggestions of good questions to ask if I get to be in front of him?


----------------------------

Chemo and ALCAR


Here are the small studies that proceeded this larger study, which they say they used as a foundation.

These seem to be less respected for reasons such as too small, uncontrolled, purely theoretical, based only on rats, etc,



Bianchi G, Vitali G, Caraceni A, et al: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750, 2005

Oncologist. 2013;18(11):1190-1. doi: 10.1634/theoncologist.2013-0061. Epub 2013 Oct 8.
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.

Pisano C, Pratesi G, Laccabue D, et al: Pacli- taxel and cisplatin-induced neurotoxicity: A protec- tive role of acetyl-L-carnitine. Clin Cancer Res 9:5756-5767, 2003

JXiao WH, Zheng H, Bennett GJ: Characteriza- tion of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 203:194-206, 2012

Zheng H, Xiao WH, Bennett GJ: Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 232:154-161, 2011

Xiao W, Naso L, Bennett GJ: Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropa- thies. Pain Med 9:505-517, 2008

Jin HW, Flatters SJ, Xiao WH, et al: Preven- tion of paclitaxel-evoked painful peripheral neuropa- thy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 210: 229-237, 2008

CNS Drugs. 2007;21 Suppl 1:39-43; discussion 45-6.
Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
De Grandis D.



This study says that ALCAR doesn't seem to decrease the effectiveness of taxol or carboplatinum and does not seem to cause ovarian cancer cells to proliferate:

Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Gynecol Oncol. Mar 2009; 112(3): 631–636.